Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade
Authors
Keywords
renal cell carcinoma, atezolizumab, bevacizumab, sunitinib, checkpoint blockade, integrated genomics, PD-L1, VHL, PBRM1, CDKN2A/B, sarcomatoid
Journal
CANCER CELL
Volume 38, Issue 6, Pages 803-817.e4
Publisher
Elsevier BV
Online
2020-11-06
DOI
10.1016/j.ccell.2020.10.011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The lysine‐specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer
- (2019) Theodoros Rampias et al. EMBO REPORTS
- Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear cell Renal Cell Cancer - Data from a Randomized Phase III Trial
- (2019) A. Ari Hakimi et al. Cancer Discovery
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.
- (2019) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- The Function of Non-Coding RNAs in Lung Cancer Tumorigenesis
- (2019) Cornelia Braicu et al. Cancers
- 910PDEfficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
- (2019) T K Choueiri et al. ANNALS OF ONCOLOGY
- 911PDA first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC
- (2019) E Jonasch et al. ANNALS OF ONCOLOGY
- Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma
- (2019) David J. Clark et al. CELL
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal
- (2018) Samra Turajlic et al. CELL
- Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal
- (2018) Samra Turajlic et al. CELL
- ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade
- (2018) Jianfeng Shen et al. NATURE MEDICINE
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sarcomatoid renal cell carcinoma: Biology and treatment advances
- (2018) Nemer El Mouallem et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art
- (2018) Cedric Lebacle et al. WORLD JOURNAL OF UROLOGY
- An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors
- (2018) Tao Wang et al. Cancer Discovery
- The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
- (2018) David A. Schaer et al. Cell Reports
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
- (2018) Christopher J. Ricketts et al. Cell Reports
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
- (2018) Martin H Voss et al. LANCET ONCOLOGY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Reactome Pathway Knowledgebase
- (2017) Antonio Fabregat et al. NUCLEIC ACIDS RESEARCH
- Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL−/−clear cell renal carcinoma
- (2017) Wenhua Gao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer
- (2017) Jing Gong et al. Cell Reports
- The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma
- (2017) Amrita M. Nargund et al. Cell Reports
- Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study
- (2016) Saeed Dabestani et al. WORLD JOURNAL OF UROLOGY
- Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma
- (2016) Fengju Chen et al. Cell Reports
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting
- (2015) B. Beuselinck et al. CLINICAL CANCER RESEARCH
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers
- (2014) Eric C. Kauffman et al. Nature Reviews Urology
- HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
- (2013) Gregg L. Semenza JOURNAL OF CLINICAL INVESTIGATION
- Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
- (2013) Payal Kapur et al. LANCET ONCOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Quantitative set analysis for gene expression: a method to quantify gene set differential expression including gene-gene correlations
- (2013) Gur Yaari et al. NUCLEIC ACIDS RESEARCH
- BAP1 loss defines a new class of renal cell carcinoma
- (2012) Samuel Peña-Llopis et al. NATURE GENETICS
- Fast and SNP-tolerant detection of complex variants and splicing in short reads
- (2010) T. D. Wu et al. BIOINFORMATICS
- Hypoxia-Inducible Factors and the Response to Hypoxic Stress
- (2010) Amar J. Majmundar et al. MOLECULAR CELL
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma
- (2009) Brian I Rini et al. LANCET
- Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy
- (2008) Ali Reza Golshayan et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search